Beatson International Cancer Conference: invasion and metastasis by Stapleton, G & Spence, H J
While the salient feature of cancer is uncontrolled cell growth and
proliferation, the most life-threatening form of the disease occurs
in the latter stages as tumours acquire the ability to invade and
metastasize to other sites in the organism. During the progression
to malignancy, changes in the regulation of motility and invasive
properties of tumour cells occur, involving changes in response to
growth factors and the extracellular matrix (ECM). Once a
secondary tumour is established, its new growth and survival is
dependent on the formation of new blood vessels to the tumour
(angiogenesis). Importantly, all of these processes occur normally
in the organism and so it is their deregulation which results in the
malignant phenotype. The fourth Beatson International Cancer
Conference, sponsored by the Cancer Research Campaign and the
Association for International Cancer Research, provided a stimu-
lating forum in which to emphasize the advances in cellular and
molecular mechanisms controlling the various stages of metas-
tasis, as well as highlighting the advances in potential therapeutic
strategies to control these latter stages of cancer.
CELL MOTILITY AND ACTIN REORGANIZATION
The locomotory machinery of the cell is central to both invasion
and metastasis. The Rho family of GTPases connect membrane
receptor signalling to cytoskeletal reorganization and the induction
of motile structures. Zigmond (Philadelphia) described the role of
Cdc42 and Rac in the regulation of actin polymerization dynamics,
by activating the Arp2/3 complex and the nucleation of actin
through Wasp. Symons (New York) proposed that while a role in
transformation for Rac, Rho and Cdc42 is established, each will
contribute individually to different aspects of transformation.
Searches for new Rac interacting proteins revealed the family of
synaptojanins whose possible functions involve endocytosis and
organization of the actin cytoskeleton, however a role in Rac-
dependent transformation is yet to be established. Deregulation of
cell–cell interactions through the cadherin receptors is another
feature of metastatic epithelial cancers, the formation and dis-
assembly of which are controlled in part through Rho GTPases.
Braga (London) highlighted a much overlooked regulatory level of
signal transduction and cadherin function: the kinetics of a given
signal. What is well-established regarding sustained versus
transient activation of the MAP kinase pathway appears to be
conserved in other signalling pathways. Whereas sustained
activation of Rac in keratinocytes leads to the formation of
cadherin-mediated cell–cell contacts, transient activation is
required for lamellipodia formation and cell motility. Using
Rac-Rho chimaeras, Braga went on to map different domains of
Rac, which, presumably through the binding of different effectors,
are required for cell–cell adhesion or lamellipodia formation.
Cadherins signal through catenins which participate in indepen-
dent signalling events through the Wnt signalling pathway.
b-catenin interacts not only at the cell membrane with cadherins,
but also in a complex with the LEF/TCF family of transcription
factors to modulate gene expression. Birchmeier (Berlin) and
Polakis (Richmond, CA) have defined the function of b-catenin in
development and tumour progression and show that the regulation
of b-catenin is determined by targeted degradation via ubiquina-
tion and the proteosome. Mutations in both b-catenin and the APC
(adenomatous polyposis coli) gene, which is also involved in Wnt
signalling and is mutated in 80% of colon cancer, affect the degra-
dation of b-catenin and allow its accumulation in the cytosol.
The influence of the microenvironment on cell fate, function
and response is of paramount importance in many cellular para-
digms but certainly in aspects of cell invasion and was a recurring
theme at this meeting. In particular, Gurdon (Cambridge) focused
on the formation of morphogen gradients during early develop-
ment where a signal generated several cell diameters away from
other cells will be interpreted differently according to the concen-
tration that a cell encounters. Cells measure their response to a
given concentration by the absolute number of morphogen-bound
receptors which in turn determines gene expression for low
response genes versus high response genes. Studies using
mammary gland further emphasized the importance of the ECM in
determining normal cellular differentiation or, when deregulated,
the induction of apoptosis, inappropriate morphogenesis or tumour
formation (Bissell, Berkeley, CA). Gallagher (Manchester) elabo-
rated on this theme by providing a molecular mechanism where
heparin sulphate proteoglycans (HSPGs) function as sensors of the
microenvironment and regulate the activation of growth factors.
The degree and manner of sulphation of HSPGs determines
binding and activation of FGF. 2-O-sulphation of the HSPG is
required for binding to FGF, then further 6-O-sulphation promotes
FGF mitogenic activity. The degree of sulphation is known to
change in malignant cells, suggesting a mechanism whereby
deregulated growth factor and chemokine signalling might occur.
The regulation of cell–cell and cell–ECM adhesions is a critical
determinant of cell motility and Frame (Glasgow) continued on
this theme, exploring the role of the proto-oncogene, c-src, in both
types of cell adhesions. Src is localized at focal adhesions, the sites
where its role appears to be in the turnover of these structures.
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focal adhesions due to a lack of focal adhesion turnover. In epithe-
lial cells, Src participates in the regulation of cell–cell contacts,
where inhibition of Src activity results in their stabilization. Thus
Src functions at multiple levels to regulate cell motility and
invasion at both cell–cell and cell–ECM contacts. Saxton and
Pawson (Toronto) addressed the regulation of receptor tyrosine
kinase and integrin signalling by protein tyrosine phosphatases.
Homozygous null Shp2 mice were generated which have noto-
chord and posterior truncated phenotypes similar to the FGF8
knockout. In addition to defects in MAP kinase signalling,
Shp2  2/2 mouse embryonic fibroblasts are defective in chemo-
tactic migration and cell spreading. Focal adhesions in these cells
are larger than in normal cells suggesting a role in focal adhesion
turnover, which is similar to that seen in FAK –/– cells and cells
expressing dominant negative Src. Because FAK and Shp2 are
shown to interact in normal fibroblasts, it is likely that Shp2
contributes to cell adhesion by regulating FAK and Src activity,
possibly by dephosphorylating and activating Src. Not surpris-
ingly, both Src and FAK expression are up-regulated in colon
cancer and squamous cell carcimomas respectively.
Yet another phosphatase involved in the regulation of FAK
activity and possibly other focal adhesion components is the
tumour suppressor PTEN/MMAC1/TEP1 which is deleted or
mutated in many advanced cancers. Aside from its role as a
regulator of the PI 3-kinase pathway by dephosphorylation of
3¢ phosphoinositides, PTEN is also a tyrosine phosphatase with
FAK as its most notable substrate. Yamada (Bethesda) showed that
in addition to regulation of integrin signalling to the MAP kinase
pathway, PTEN determines the phosphorylation state of the
adaptor, Shc, which is required for MAP kinase signalling from
growth factor receptors. Interestingly, by tracking cell movements
on fibronectin, Yamada was able to define two distinct but additive
mechanisms of PTEN-regulated MAP kinase activation where Shc
and MAP kinase are involved in random migration movements,
whereas FAK and focal adhesion assembly are involved in
directed cell movement. Perhaps the coordination of two such
pathways is used by the cell to regulate the speed and direction of
movement separately.
CELL INVASION
The growth of benign tumours respects cellular boundaries,
remaining confined to tissue compartments. During the transition
to an invasive carcinoma, tumour cells actively penetrate the
epithelial basement membrane and intermix with other cell types.
Again the interplay between a cell and the extracellular environ-
ment will be crucial in facilitating cell invasion. The up-regulation
and secretion of ECM-degrading proteases, in particular the
matrix metalloproteinases (MMPs) are invariably linked to
malignant progression. Stromelysin-1 (MMP-3) and gelatinase
B (MMP-9) are expressed in the stromal compartment and are
capable of degrading multiple ECM components. Transgenic mice
carrying tetracycline-inducible expression of MMP-3 in the
mammary gland have phenotypically normal epithelial glandular
structures in the absence of MMP-3, but form invasive
mesenchymal tumours when MMP-3 is expressed (Werb, San
Francisco, CA). Importantly, once initiated, tumour formation
becomes independent of MMP-3 expression indicating that MMP-
3 functions in the early stages of tumour progression. Conversely,
Matrilysin (MMP-7) is localized to the apical surface of epithelial
cells and thus does not contact the basement membrane.
Nevertheless MMP-7 overexpression in transgenic mice acceler-
ates the formation of neu-induced metastatic tumours. Conversely,
a reduction in tumours is seen in mice with a deleted APC gene
when crossed with MMP-7 2/2 mice (Matrisian, Nashville, TN).
Significantly, these studies indicate that of the 20 or so MMP
proteins, each appears to act in different cell types or at different
stages of tumour progression.
The hyaluronan receptor, CD44, links the ECM to intracellular
responses primarily through interaction with ERM (Ezrin-
Radixin-Moesin) proteins which serve to link the plasma
membrane to the intracellular cytoskeleton. Isacke (London)
addressed the intracellular associations of CD44 with ezrin and the
regulation of the interaction by phosphorylation events. Ezrin
activation and localization to the membrane is dependent on
unfolding of the protein through phosphorylation events. Ezrin is
known to interact with a number of proteins including positive
and negative regulators of Rho GTPase. Mangeat (Montpellier)
mimicked this opened molecule by inserting Green Fluorescent
Protein into the middle of Ezrin to induce its unfolding, as a means
to further understand the functional determinants of the molecule.
Herrlich (Karlsruhe) showed that another ERM protein, Merlin,
also associates with CD44 and inhibits Schwannoma growth in
nude mice. The extracellular domain of CD44 is proposed to regu-
late growth factor processing and presentation. CD44 interacts
with regulatory components important for invasion including
MMP-9 and growth factors, and is required for activation of the
c-Met receptor and consequent scattering and invasion. CD44
plays a role in growth factor presentation by regulating the
cleavage of the HGF precursor. The mechanisms of how CD44
does this is not known, however, CD44 is in close proximity with
other molecules such as the urokinase-type plasminogen activator
receptor which are required for growth factor activation.
HGF-mediated cell scattering and invasion is blocked by CD44
antibodies; the same antibodies will also inhibit metastasis in
mice.
It is clear, however, that cells will require the coordinated
activity of many gene products in order to become invasive. This
issue was addressed by Ozanne (Glasgow), who described the
results of large scale screens designed to identify those genes
which are required for or contribute to cell invasion as well as
genes which need to be suppressed for transformation to occur.
Based on the premise that the transcription factor, AP-1, controls
expression of genes required for invasion, a number of AP-1-
dependent gene products including CD44 and ezrin as well as
many novel genes have been identified and verified as
contributing to aspects of cell invasion.
THE SIGNIFICANCE OF ANGIOGENESIS AND
VASCULARIZATION IN CANCER PROGRESSION
Tumours require the formation of new blood vessels to support
their growth (the process of angiogenesis), providing the basis
for presentations by the keynote speaker Judah Folkman (Boston)
and Rakesh Jain (Boston). Folkman emphasized the scope for
therapeutic intervention provided by the many known natural acti-
vators (e.g. bFGF, VEGF) and inhibitors (e.g. Thrombospondin-1,
Angiostatin) of angiogenesis. Significantly, the receptors for
angiogenic factors remain to be identified and will undoubtedly
provide additional levels of intervention once identified. Jain
has developed a novel in vivo microscopy that allows direct
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cellular level. This approach has provided powerful insight not
only into angiogenesis and blood flow in tumours, but also
leucocyte adhesion and vascular permeability. This methodology
showed, for example, that the pore sizes in the walls of tumour
blood vessels depend not only on tumour type, but also the site of
tumour growth, factors which have important implications for the
delivery of drugs and gene carriers to tumours.
Given that integrin alpha-v expression is up-regulated during
angiogenesis and by angiogenic growth factors, and is the
successful target of anti-angiogenic therapies, it was with some
surprise that mice with targeted disruptions in all alpha-v integrins
display normal angiogenesis and vascularization (Hynes,
Cambridge, MA). While clarification of these discordant results
awaits, it may be that other integrins such as a5b1, a1b1 and a2b1
integrins, which also appear to be involved in angiogenesis, are
able to compensate for the lack of alpha-v integrins in these mice.
THERAPEUTIC STRATEGIES TO CIRCUMVENT
METASTASIS
Successful metastatic progression requires the completion of all of
the above described processes, providing many levels of attack for
therapeutic intervention. In the long-term, those genes identified in
the screens described by Ozanne will be of great informative value
when arrayed onto microchips and used to screen tumours, thereby
identifying new potential targets for intervention.
Angiogenesis
The idea that successful metastatic progression is totally depen-
dent on the formation of new blood vessels and a blood supply to
support new tumour growth has vastly expanded the potential
for new approaches to anticancer therapies. In addition, cancer
therapy directed at non-malignant, and therefore genetically stable,
endothelial cells reduces the chances of mutation to drug-resistant
variants. Currently, there are 19 clinical trials underway in the
USA aimed at various levels of angiogenesis, six of which are in
phase III. Drugs designed to block endothelial cells include
Endostatin, a C-terminal product of collagen XVIII, which inhibits
endothelial cell proliferation and migration. Other modes of attack
include blocking activators of angiogenesis such as the phase II
trials underway using anti-VEGF antibodies in patients with
metastatic kidney cancer.
Drug design based on inhibitors of MMPs
A greater understanding of MMP function will undoubtedly point
the way toward therapeutic intervention, targeted either at the
proteinases themselves, or at new molecular targets downstream of
the proteinases. A number of synthetic and naturally occurring
MMP inhibitors are currently in clinical trials. One such endoge-
nous inhibitor of MMP-3, TIMP-1 (tissue inhibitor of metallopro-
teinases-1), when overexpressed, is able to quench the ability of
MMP-3 to promote neoplasia in transgenic mice. However, the
work of Werb clearly shows that at least some MMPs, like MMP-
3, function early in metastatic progression, and thus therapeutic
targeting will be of little use once the tumour has progressed. In
these cases, downstream targets of MMPs may be of greater
clinical use.
While it is clear that the mechanisms of metastatic progression
are highly complex and not completely understood, the optimism
and enthusiasm generated by the progress presented at the Beatson
Conference clearly points a way forward for future medical
intervention.
Beatson International Cancer Conference 1617
British Journal of Cancer (2000) 82(9), 1615–1617 © 2000 Cancer Research Campaign